Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 428 across all filing types
Latest filing 2023-11-09 Earnings Release
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the quarter and half year ended September 30, 2023. It contains key financial highlights such as total income, EBITDA, net profit, and EPS for Q2 and H1 FY24. The document is dated November 9, 2023, and is addressed to the National Stock Exchange of India. It is not a full financial report but an initial announcement of quarterly/periodical financial results. Therefore, it fits the definition of an Earnings Release (ER). The document length is 4621 characters, which is consistent with a press release rather than a full interim report. Hence, the classification is ER with high confidence. H1 2024
2023-11-09 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding the publication of unaudited financial results for the quarter and half year ended September 30, 2023. It references Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which mandates the disclosure of financial results. The document includes financial data tables and mentions the publication of these results in newspapers. The content is focused on quarterly and half-year financial results, which are unaudited and for a period shorter than a full fiscal year. The document is not a full annual report, audit report, or earnings release but a comprehensive interim financial report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) supports that it is a full report rather than a brief announcement or certification. H1 2024
2023-11-09 English
Financial Result Updates
Regulatory Filings
2023-11-08 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a forthcoming Board Meeting scheduled for November 8, 2023, where the company will consider and approve standalone unaudited financial results for the quarter and half year ended September 30, 2023. It also mentions the closure of the trading window for insiders. The document is an intimation to the stock exchange about the board meeting and does not contain any actual financial results or detailed reports. The length is short (2280 characters), and it serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-11-01 English
Board Meeting — VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 08-Nov-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2023-11-01 English
Press Release (Revised)
Regulatory Filings Classification · 95% confidence The document is a press release announcing the introduction of a new brand "HealthE" and its product line by Vaishali Pharma Limited. It is addressed to the National Stock Exchange of India and includes promotional and business information about the company and the new product. There are no financial statements, regulatory filings, voting results, or management changes detailed. The content is primarily an announcement of a business development rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories.
2023-10-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.